• 1
    Teel P. Vascular invasion as a prognostic factor in breast carcinoma. Surg Gynecol Obstet. 1964; 118: 1006-1008.
  • 2
    Lee AH, Pinder SE, Macmillan RD, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer. 2006; 42: 357-362.
  • 3
    Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994; 24: 41-47.
  • 4
    Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer. 1995; 76: 1772-1778.
  • 5
    Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995; 87: 19-27.
  • 6
    Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989; 7: 1239-1251.
  • 7
    de Mascarel I, Bonichon F, Durand M, et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998; 34: 58-65.
  • 8
    Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol. 1990; 8: 1457-1465.
  • 9
    Clemente CG, Boracchi P, Andreola S, Del Vecchio M, Veronesi P, Rilke FO. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer. 1992; 69: 1396-1403.
  • 10
    Sundquist M, Thorstenson S, Klintenberg C, Brudin L, Nordenskjold B. Indicators of loco-regional recurrence in breast cancer. The South East Swedish Breast Cancer Group. Eur J Surg Oncol. 2000; 26: 357-362.
  • 11
    Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004; 240: 306-312.
  • 12
    Rosen PP, Saigo PE, Braun DW Jr, Weathers E, DePalo A. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg. 1981; 193: 15-25.
  • 13
    Weigand RA, Isenberg WM, Russo J, Brennan MJ, Rich MA. Blood vessel invasion and axillary lymph node involvement as prognostic indicators for human breast cancer. Cancer. 1982; 50: 962-969.
  • 14
    Debled M, de Mascarel I, Brouste V, Mauriac L, MacGrogan G. Re: population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst. 2010; 102: 275-276; author reply 276-277.
  • 15
    Ejlertsen B, Jensen MB, Rank F, et al. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst. 2009; 101: 729-735.
  • 16
    Colleoni M, Rotmensz N, Maisonneuve P, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol. 2007; 18: 1632-1640.
  • 17
    Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000; 191: 1-6; discussion 6-8.
  • 18
    Davis BW, Gelber R, Goldhirsch A, et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol. 1985; 16: 1212-1218.
  • 19
    Pathology Reporting Of Breast Disease. A Joint Document Incorporating the 3rd Edition of the National Health Service (NHS) Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the 2nd Edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. Sheffield, United Kingdom. NHSBSP Publication No 58. January 2005.
  • 20
    de Wolf CJM, Perry NM, eds. European Commission. European Guidelines for Quality Assurance in Mammography Screening. Luxembourg: Office for Official Publications of the European Communities; 1996.
  • 21
    Fitzgibbons PL, Connolly JL, Page DL. Breast: Protocol Applies to All Invasive Carcinomas of the Breast. Northfield, IL: College of American Pathologists; 2005.
  • 22
    Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
  • 23
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
  • 24
    Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009; 10: 1070-1076.
  • 25
    Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer [serial online]. Breast Cancer Res. 2010; 12: R1.
  • 26
    Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22: 207-219.
  • 27
    Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006; 4( suppl 1): S1-S26.
  • 28
    Mohammed RA, Martin SG, Mahmmod AM, et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol. 2011; 223: 358-365.
  • 29
    Rosen PP. Rosen's Breast Pathology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2009.
  • 30
    Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer. 2006; 94: 1643-1649.
  • 31
    Tezuka K, Onoda N, Takashima T, et al. Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients. Oncol Rep. 2007; 17: 997-1003.
  • 32
    Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992; 20: 479-489.
  • 33
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.
  • 34
    Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade [serial online]. Breast Cancer Res. 2010; 12: 207.
  • 35
    Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006; 208: 495-506.
  • 36
    Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008; 26: 3153-3158.
  • 37
    Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into 2 clinically distinct subgroups. Breast Cancer Res Treat. 2011; 127: 591-599.
  • 38
    Macmillan RD, Barbera D, Hadjiminas DJ, et al. Sentinel node biopsy for breast cancer may have little to offer 4-node-samplers. results of a prospective comparison study. Eur J Cancer. 2001; 37: 1076-1080.
  • 39
    Liljegren G, Holmberg L, Bergh J, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999; 17: 2326-2333.
  • 40
    Ragage F, Debled M, MacGrogan G, et al. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer? Cancer. 2010; 116: 3093-3101.
  • 41
    Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14: 5158-5165.
  • 42
    Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures [serial online]. Breast Cancer Res. 2008; 10: R65.
  • 43
    Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 10 355: 560-569, 2006.
  • 44
    Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20: 1319-1329.
  • 45
    O'Rourke S, Galea MH, Morgan D, et al. Local recurrence after simple mastectomy. Br J Surg. 1994; 81: 386-389.
  • 46
    Locker AP, Ellis IO, Morgan DA, Elston CW, Mitchell A, Blamey RW. Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg. 1989; 76: 890-894.
  • 47
    Cheng SH, Horng CF, Clarke JL, et al. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006; 64: 1401-1409.